Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.
Back to dashboard
Company Information
About this company
Key people
William P. Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
Grant Yonehiro
Chief Operating Officer
Sheila Gujrathi
Chief Strategy Officer, Director
Laura Berner
Independent Director
Jakob Dupont
Independent Director
Kathleen D. Laporte
Independent Director
Brian O'Callaghan
Independent Director
Nicole Onetto
Independent Director
Click to see more
Key facts
- Shares in issue2.59m
- EPICBOLT
- ISINUS0977022039
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$16.91m
- Employees23
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.